Palisade Bio, Inc. cash flow to debt ratio of -15.28K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Palisade Bio, Inc.'s free cash flow has increased -11.04% from $-12.19M last year to $-10.85M, signaling increasing performance

Palisade Bio, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Palisade Bio, Inc.'s debt has decreased relative to shareholder equity from 0.02 last year to 0.00 today, signaling strengthened financials

Palisade Bio, Inc. has a net cash position, so leverage is healthy.

Palisade Bio, Inc.'s interest coverage ratio is -5.89K, which means that the company struggles to meet interest obligations, signaling financial risk.

Palisade Bio, Inc. has insufficient data to evaluate this check.

Palisade Bio, Inc.'s short-term assets of $134.22M exceed its short-term liabilities of $4.64M

Palisade Bio, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Palisade Bio, Inc.'s return on equity of -33.47%, is lower than 15.00%, indicating bad performance

Palisade Bio, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Palisade Bio, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Palisade Bio, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Palisade Bio, Inc. has negative free cash flow, indicating cash burn

Palisade Bio, Inc.'s yearly earnings has decreased 16.23% since last year from $-14.44M to $-16.78M, signaling decreasing performance

Palisade Bio, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -28.96% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Palisade Bio, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Palisade Bio, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Palisade Bio, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Palisade Bio, Inc. is overvalued relative to its fair value price of 0.42 based on Discounted Cash Flow model

Palisade Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Palisade Bio, Inc. is overvalued relative to its fair value price of 0.05 based on EBITDA multiple model

Palisade Bio, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Palisade Bio, Inc. has insufficient data to evaluate this check.

Palisade Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Palisade Bio, Inc. has a price-to-book ratio of 3.65x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Palisade Bio, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue